Mentality: hallucinations, excitement, insomnia.
CNS: headache, dizziness, tremor.
Cardio-vascular system: arterial hypotension or hypotension.
Respiratory system: dyspnea.
Digestive tract: nausea, vomiting, gastric pain, hyper salivation, insignificant change of hepatic function indexes, diarrhea.
Skin: redness, urticaria, exanthem.
General disorders: increase of body temperature, fever sensation, trembling, and edema.
Injection: The commonly observed adverse effects (0.1-5%) with intravenous use of Citicoline were rash, insomnia, occurrence or intensification of numbness of paralyzed extremities (when used in patients with post-apoplectic hemiplegia), nausea, abnormal laboratory values for function of the liver, and feeling of warmth. The other adverse reactions (<0.1%) were excitation, convulsions, anorexia, transient diplopia, transient blood pressure changes, malaise, shock, distressed feeling of the chest, and dyspnoea. In a short-term, placebo-controlled, crossover study, 12 healthy adults took Citicoline at daily doses of 600 mg and 1,000 mg or placebo for consecutive 5-day periods. Transient headaches occurred in 4 subjects on the 600 mg dose, 5 on the 1,000 mg dose, and 1 on placebo. No changes or abnormalities were observed in haematology, clinical biochemistry or neurological tests. A large drug surveillance study analysed the results of Citicoline treatment in 2,817 patients aged 60 to 80 years, suffering from senility and cerebral vascular insufficiency. A total of 151 incidents of side effects were recorded, representing 5% of the patient sample. The most common adverse effects were transient in nature and included stomach pain and diarrhoea in 102 cases. Vascular symptoms of hypotension, tachycardia or bradycardia occurred in 16 cases.
View ADR Monitoring Form